Ralf Nass is an Endocrinology/Metabolic physician affiliated with University of Virginia. OpenAlex indexes 73 publications with 2,877 citations (h-index 24); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
415 Ray C. Hunt Drive
Charlottesville, VA 229030001
Telephone
434-924-1825Registry record last updated 24 Apr 2014.
Clinical trials
- Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers
Sponsor: Daniel Chernavvsky, MD
- InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy
Sponsor: University of Virginia
- The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
66.9%Insulin Analog23.1%Lantus Solostar33%Novolog Flexpen16%Tresiba Flextouch U-10011%Humalog Kwikpen U-1009%Basaglar Kwikpen U-1008%Lantus6%Humalog5%Insulin Lispro Kwikpen U-1004%Novolog4%Fiasp Flextouch3%Part D<11 patientsGLP-1 receptor agonist11.4%Trulicity57%Ozempic35%Mounjaro8%Part D<11 patients+ 7 more classes in this area
Hormonal (systemic)
19.1%l-Thyroxine15.5%Levothyroxine Sodium82%Synthroid18%Part D<11 patientsMineralocorticoids1.4%Fludrocortisone Acetate100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
7.8%Statin4.2%Atorvastatin Calcium42%Rosuvastatin Calcium32%Pravastatin Sodium27%Part D<11 patientsACE inhibitor1.1%Lisinopril100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2005–2010 per NIH RePORTER. The latest:
- THE IMPACT OF INSULIN ON THE SHORT-TERM REGULATION OF GHRELIN
University of Virginia
FY2010$100,231M01RR000847 - MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AWARD
University of Virginia
FY2009$131,323K23RR018770 - THE IMPACT OF INSULIN ON THE SHORT-TERM REGULATION OF GHRELIN
University of Virginia
FY2009$54,596M01RR000847
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Deboer, MD
University of Virginia
Peter Lobo, MD
University of Virginia
Frederick Hayden, MD
University of Virginia
Charles Landen, MD
University of Virginia
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”